DermTech, Inc. provided revenue guidance for the first quarter and full year of 2022. Management estimates that first quarter 2022 assay revenue will be between $3.4 million and $3.8 million, and full year 2022 assay revenue will be between $22 million and $26 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.303 USD | -3.93% | -22.31% | -82.69% |
14/05 | DermTech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
14/05 | Earnings Flash (DMTK) DERMTECH Posts Q1 Revenue $3.8M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-82.69% | 1.06Cr | |
-4.32% | 1.24TCr | |
-0.60% | 843.33Cr | |
+6.82% | 576.58Cr | |
-10.21% | 410.34Cr | |
-60.35% | 265.63Cr | |
+10.62% | 266.4Cr | |
-7.60% | 239.16Cr | |
+16.77% | 202.29Cr | |
-9.18% | 177.15Cr |
- Stock Market
- Equities
- DMTK Stock
- News DermTech, Inc.
- DermTech, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022